In a significant breakthrough for cancer treatment options, Tanvex BioPharma USA, Inc. ("Tanvex" or the "Company") announced that the FDA has approved their biosimilar product NYPOZI (filgrastim-txid) and accepted their Biologics License Application (BLA) for TX-05. These milestones highlight
Accenture, a global professional services company renowned for its expertise in strategy, consulting, and technology, has made a strategic investment in Earli Inc., a biotechnology firm dedicated to revolutionary early cancer detection. This strategic move is managed through Accenture Ventures and
AN2 Therapeutics, a prominent biopharmaceutical company, has announced a major restructuring of its operations following an unexpected clinical trial outcome. This decision marks a significant strategic pivot from their previous research initiatives and has substantial implications for the
The latest findings from Kiromic BioPharma’s phase 1/2 clinical trial spotlight the promising potential of its investigational therapy, Deltacel (KB-GDT-01), an allogeneic gamma delta T-cell (GDT) therapy. This novel therapy is being evaluated for patients with non-small cell lung cancer (NSCLC)
The biotech industry, much like any other sector, has been significantly impacted by the COVID-19 pandemic. The extraordinary boom in 2020 and 2021 led to an influx of investments and an unprecedented surge in innovations. However, as the world transitions into a post-pandemic era, the biotech
A groundbreaking advancement in tumor immunotherapy is unfolding with the approval of a new mRNA vaccine for Epstein-Barr virus (EBV) positive tumors by China's National Medical Products Administration (NMPA) for Phase-I clinical trials. Developed independently by WestGene Biopharma Co., Ltd.,
